| Followers | 83 |
| Posts | 36201 |
| Boards Moderated | 0 |
| Alias Born | 03/09/2010 |
Saturday, November 03, 2012 7:27:07 PM
LOL LOL that was FIVE years ago. LOL LOL meanwhile:
1 Completed Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- ? -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered Naltrexone
Condition: Healthy
Intervention: Drug: ALO-02 (Oxycodone Naltrexone)
2 Completed Pharmacokinetics Study of ALO-02 and OxyContin
Condition: Management of Moderate to Severe Pain
Interventions: Drug: ALO-02; Drug: Naltrexone block; Drug: OxyContin
3 Recruiting The Evaluation Of ALO-02 (Oxycodone Hcl and Naltrexone Hcl) In Subjects With Moderate To Severe Chronic Low Back Pain
Condition: Chronic Pain
Interventions: Drug: ALO-02; Drug: Placebo
4 Completed A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers
Condition: Healthy
Interventions: Drug: Oxycodone controlled-release test formulation; Drug: Immediate-release reference drug
5 Completed Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain
Condition: Chronic Noncancer Pain
Intervention: Drug: oxycodone HCl and naltrexone HCl extended-release capsules
6 Recruiting Study to Determine the Effects of Co-Administration of Alcohol on the Absorption of Oxycodone From a Proprietary Controlled-Release Formulation
Condition: Healthy
Interventions: Drug: Test formulation administered with water; Drug: Test formulation administered with 20% ethanol; Drug: Test formulation administered with 40% ethanol
7 Completed Pharmacokinetics And Relative Bioavailability Study Of Oxycodone
Condition: Management of Moderate to Severe Pain
Intervention: Drug: Oxycodone
8 Completed A Study To Characterize The Pharmacokinetics Of Oxycodone In Healthy Volunteers
Condition: Management of Moderate to Severe Pain
Intervention: Drug: Oxycodone
9 Not yet recruiting Pharmacokinetics And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers
Condition: Healthy
Intervention: Drug: Oxycodone
To Top
1 Recruiting A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain
Condition: Low Back Pain
Interventions: Drug: Oxycodone/Naloxone controlled-release; Drug: Oxycodone HCl controlled-release; Drug: Placebo
2 Recruiting Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain
Condition: Low Back Pain
Interventions: Drug: Oxycodone/Naloxone controlled-release; Drug: Oxycodone HCl controlled-release; Drug: Placebo
3 Active, not recruiting Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain
Condition: Low Back Pain
Interventions: Drug: Oxycodone/Naloxone Controlled-release; Drug: Placebo
http://clinicaltrials.gov/ct2/results?term=oxycodone+purdue+naloxone&Search=Search - wrapper
1 Completed Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- ? -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered Naltrexone
Condition: Healthy
Intervention: Drug: ALO-02 (Oxycodone Naltrexone)
2 Completed Pharmacokinetics Study of ALO-02 and OxyContin
Condition: Management of Moderate to Severe Pain
Interventions: Drug: ALO-02; Drug: Naltrexone block; Drug: OxyContin
3 Recruiting The Evaluation Of ALO-02 (Oxycodone Hcl and Naltrexone Hcl) In Subjects With Moderate To Severe Chronic Low Back Pain
Condition: Chronic Pain
Interventions: Drug: ALO-02; Drug: Placebo
4 Completed A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers
Condition: Healthy
Interventions: Drug: Oxycodone controlled-release test formulation; Drug: Immediate-release reference drug
5 Completed Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain
Condition: Chronic Noncancer Pain
Intervention: Drug: oxycodone HCl and naltrexone HCl extended-release capsules
6 Recruiting Study to Determine the Effects of Co-Administration of Alcohol on the Absorption of Oxycodone From a Proprietary Controlled-Release Formulation
Condition: Healthy
Interventions: Drug: Test formulation administered with water; Drug: Test formulation administered with 20% ethanol; Drug: Test formulation administered with 40% ethanol
7 Completed Pharmacokinetics And Relative Bioavailability Study Of Oxycodone
Condition: Management of Moderate to Severe Pain
Intervention: Drug: Oxycodone
8 Completed A Study To Characterize The Pharmacokinetics Of Oxycodone In Healthy Volunteers
Condition: Management of Moderate to Severe Pain
Intervention: Drug: Oxycodone
9 Not yet recruiting Pharmacokinetics And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers
Condition: Healthy
Intervention: Drug: Oxycodone
To Top
1 Recruiting A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain
Condition: Low Back Pain
Interventions: Drug: Oxycodone/Naloxone controlled-release; Drug: Oxycodone HCl controlled-release; Drug: Placebo
2 Recruiting Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain
Condition: Low Back Pain
Interventions: Drug: Oxycodone/Naloxone controlled-release; Drug: Oxycodone HCl controlled-release; Drug: Placebo
3 Active, not recruiting Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain
Condition: Low Back Pain
Interventions: Drug: Oxycodone/Naloxone Controlled-release; Drug: Placebo
http://clinicaltrials.gov/ct2/results?term=oxycodone+purdue+naloxone&Search=Search - wrapper
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
